Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126116 | 0.97 | HDAC8 (0.48) | HDAC8HDAC6HDAC1KDM1AKCNH2 | |
| SCHEMBL21609716 | 0.97 | HDAC8 (0.48) | HDAC8HDAC6HDAC1KDM1AKCNH2 | |
| SCHEMBL30056544 | 0.97 | HDAC8 (0.48) | HDAC8HDAC6HDAC1KDM1AKCNH2 | |
| SCHEMBL17061138 | 0.97 | HDAC8 (0.48) | HDAC8HDAC6HDAC1KDM1AKCNH2 | |
| SCHEMBL233178 | 0.95 | ESR2 (0.47) | HDAC8HDAC6HDAC1KDM1AKCNH2 | |
| SCHEMBL14804315 | 0.89 | KDM1A (0.48) | KDM1AKCNH2MAOBRCOR1KDM1B | |
| SCHEMBL265495 | 0.89 | KDM1A (0.48) | KDM1AKCNH2MAOBRCOR1KDM1B | |
| SCHEMBL781509 | 0.86 | HDAC1 (0.54) | HDAC8HDAC6HDAC1ESR2NOTUM | |
| SCHEMBL25274751 | 0.85 | HDAC8 (0.41) | HDAC8HDAC6HDAC1KDM1AKCNH2 | |
| Pyrrolidine SCHEMBL9026279 | 0.85 | CYP2D6 (0.45) | HDAC8HDAC6HDAC1KCNH2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-117510421-B | Fluorine-containing benzotriazolyl fluorescent compound for optical transfer film and synthesis method thereof | 河北美星化工有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117616028-A | 2, 8-dihydropyrazolo [3,4-B ] indole derivatives for the treatment of cancer | 默克专利股份公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117510421-A | Fluorine-containing benzotriazolyl fluorescent compound for optical transfer film and synthesis method thereof | 河北美星化工有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| CN-115515959-A | Tricyclic heterocycles as TEAD binders | 默克专利股份公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-107286953-B | Cyclopentyl negative dielectric anisotropy liquid crystal compound and composition and application thereof | 北京八亿时空液晶科技股份有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| WO-2007090752-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
| US-6639107-B1 | Potentiating glutamate receptor function | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1246797-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001042203-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | HDAC8 425/4885HDAC6 401/4885HDAC1 86/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | HDAC8 773/4885HDAC6 1725/4885HDAC1 734/4885 |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, TEAD2 | HDAC8 1465/4885HDAC6 314/4885HDAC1 1334/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | HDAC8 4068/4885HDAC6 3172/4885HDAC1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.